NCT02593942

Brief Summary

Total intravenous anaesthesia using propofol and remifentanil are routinely used drugs for this purpose. The hemodynamic stability and at the same time early emergency are the main goals following neurosurgery. However there is no standard for discontinuation time for manually controlled systems today. The investigators aimed to study the effect of remifentanil infusion alone for early emergence and hemodynamic stability during the closure period in patients undergoing supratentorial craniotomy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jan 2015

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2015

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2015

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

October 3, 2015

Completed
1 month until next milestone

First Posted

Study publicly available on registry

November 2, 2015

Completed
Last Updated

November 2, 2015

Status Verified

October 1, 2015

Enrollment Period

8 months

First QC Date

October 3, 2015

Last Update Submit

October 29, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Time of extubation

    After the surgery, starting from three-pin head holder removal, an investigator asked each patient to open his or her eyes, squeeze the investigator's hand. When the patient opened his or her eyes, obeyed commands, resumed adequate respiration, hemodynamically stable and bispectral index spectrum \> 70-80 was extubated, and the time will be recorded. The patients will be followed for an expected average of 3 hours.

    3 hours

Secondary Outcomes (3)

  • Heart Rate

    6 hours

  • Mean arterial pressure were recorded

    6 hours

  • Post-anesthesia awaking time

    3 hours

Study Arms (2)

group I

EXPERIMENTAL

remifentanil

Drug: Remifentanil

group II

EXPERIMENTAL

remifentanil, propofol

Drug: RemifentanilDrug: Propofol

Interventions

0.1-0.5 mcg/kg/min infusion

Also known as: Ultiva
group Igroup II

75-200 mcg/kg/min infusion

group II

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • American Society of Anaesthesiologist physical status I-II
  • Glasgow Coma Scale score of 15 points
  • Elective supratentorial craniotomy for tumor resection
  • Supine position

You may not qualify if:

  • Obese patient
  • Brain tumor greater than 30 mm in diameter
  • Postoperative cranial drainage
  • Hypertension
  • Diabetes mellitus
  • Reoperation
  • Pregnant
  • Breast feeding
  • Allergy to the study medications
  • History of cranial radiotherapy
  • Frontal bone flap
  • Intraoperative neuromonitoring

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Yeditepe University Hospital

Istanbul, 34752, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Supratentorial Neoplasms

Interventions

RemifentanilPropofol

Condition Hierarchy (Ancestors)

Brain NeoplasmsCentral Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteNeoplasmsBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

PropionatesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbons

Study Officials

  • Hatice Ture, MD.

    Yeditepe University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

October 3, 2015

First Posted

November 2, 2015

Study Start

January 1, 2015

Primary Completion

September 1, 2015

Study Completion

September 1, 2015

Last Updated

November 2, 2015

Record last verified: 2015-10

Locations